ResMed Inc (ASX:RMD) Chairman and Chief Executive Officer Michael J. Farrell disposed of 4,993 shares of ResMed common stock on 11 November 2026, according to a Statement of Changes in Beneficial Ownership filed with the United States Securities and Exchange Commission.

Key Points

  • Michael J. Farrell sold 4,993 shares of ResMed common stock on 11 November 2026 at a weighted average price of $235.3473, with individual trades ranging from $231.7956 to $237.600.
  • The sale was preceded by the exercise of two tranches of stock options: 683 shares and 4,310 shares, both at an exercise price of $146.34 per share.
  • Following the transactions, Farrell directly held 479,803 shares of ResMed common stock, with an additional 2,090 shares held indirectly through the Lisette and Michael Farrell Family Trust.
  • All transactions were conducted under a Rule 10b5-1 plan adopted on 31 October 2024.

Share Sale and Options Exercise on 11 November 2026

According to the filing, Farrell exercised two tranches of ResMed common stock options on 11 November 2026. The first tranche comprised 683 options and the second comprised 4,310 options, both at an exercise price of $146.34 per share. Following the exercise of these options, Farrell sold a total of 4,993 shares of ResMed common stock at a weighted average sale price of $235.3473. The filing disclosed that the sale was executed across multiple trades at prices ranging from $231.7956 to $237.600 per share.

Stock Option Details and Vesting Schedule

The filing disclosed that the two tranches of options exercised on 11 November 2026 carry an expiration date of 21 November 2026. Both tranches first became exercisable on 11 November 2020. The filing states that the options vest at one-third per year. Following the exercise and sale transactions, the remaining balance of directly held derivative securities associated with the first option tranche was 4,310, while the balance for the second tranche was reduced to zero, as disclosed in Table II of the filing.

Beneficial Ownership Following the Transactions

After completing the reported transactions, Farrell directly held 479,803 shares of ResMed common stock. An additional 2,090 shares were reported as indirectly held through the Lisette and Michael Farrell Family Trust. The filing confirmed that all transactions were executed pursuant to a Rule 10b5-1 trading plan that Farrell adopted on 31 October 2024. The form was signed by Michael J. Farrell in his capacity as Chairman and CEO and was dated 10 November 2026.